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Abstract
Circulating tumor DNA (ctDNA) is a source of mutant DNA found in plasma and holds great promise in
guiding cancer diagnostics, prognostics, and treatment. However, ctDNA fragments are challenging to detect
in plasma due to their low abundance compared to wild-type DNA. In this study, a series of ion-tagged
oligonucleotides (ITO) were synthesized using thiol-ene click chemistry and designed to selectively anneal
target DNA. The ITO-DNA duplex was subsequently captured using a hydrophobic magnetic ionic liquid
(MIL) as a liquid support. Extracted target DNA was quantified by adding the DNA-enriched MIL to the
quantitative polymerase chain reaction (qPCR) buffer to streamline the extraction procedure. Clinically
relevant concentrations of the mutation prone KRASfragment, which has been linked to colorectal, lung, and
bladder cancer, were preconcentrated using the ITO-MIL strategy allowing for enrichment factors as high as
19.49 ± 1.44 from pure water and 4.02 ± 0.50 from 10-fold diluted plasma after a 1 min extraction.
Preconcentration could only be achieved when adding the ITO probe to the sample validating the selectivity
of the ITO in the capture process. In addition, the amplification efficiency of qPCR was not affected when
performing extractions from a diluted-plasma matrix demonstrating that the ITO-MIL approach coupled to
direct-qPCR can be used to quantitate DNA from complex matrices. In comparison, commercially available
steptavidin-coated magnetic beads were observed to lose selectivity when performing extractions from a
10-fold diluted plasma matrix. The selectivity of the ITO-MIL method, coupled with the ability to rapidly
preconcentrate clinically relevant concentrations of target DNA from 10-fold diluted plasma, suggests that this
method has the potential to be applied towards the extraction of ctDNA fragments from clinical samples.
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using Ion-tagged Oligonucleotides Coupled to qPCR Compatible Magnetic Ionic Liquid 2 
Solvents 3 
Miranda N. Emaus, Marcelino Varona, and Jared L. Anderson* 4 
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Abstract 6 
 Circulating tumor DNA (ctDNA) is a source of mutan DNA found in plasma and holds 7 
great promise in guiding cancer diagnostics, prognostics, and treatment. However, ctDNA 8 
fragments are challenging to detect in plasma due to their low abundance compared to wild-type 9 
DNA. In this study, a series of ion-tagged oligonucleotides (ITO) were synthesized using thiol-10 
ene click chemistry and designed to selectively anne l target DNA. The ITO-DNA duplex was 11 
subsequently captured using a hydrophobic magnetic ioni  liquid (MIL) as a liquid support. 12 
Extracted target DNA was quantified by adding the DNA-enriched MIL to the quantitative 13 
polymerase chain reaction (qPCR) buffer to streamline the extraction procedure. Clinically 14 
relevant concentrations of the mutation prone KRAS fragment, which has been linked to 15 
colorectal, lung, and bladder cancer, were preconcentrat d using the ITO-MIL strategy allowing 16 
for enrichment factors as high as 19.49 ± 1.44 from pure water and 4.02 ± 0.50 from 10-fold 17 
diluted plasma after a 1 min extraction. Preconcentration could only be achieved when adding 18 
the ITO probe to the sample validating the selectivity of the ITO in the capture process. In 19 
addition, the amplification efficiency of qPCR was not affected when performing extractions 20 
from a diluted-plasma matrix demonstrating that the ITO-MIL approach coupled to direct-qPCR 21 
can be used to quantitate DNA from complex matrices. In comparison, commercially available 22 
steptavidin-coated magnetic beads were observed to lose selectivity when performing extractions 23 
from a 10-fold diluted plasma matrix. The selectivity of the ITO-MIL method, coupled with the 24 
ability to rapidly preconcentrate clinically relevant concentrations of target DNA from 10-fold 25 
diluted plasma, suggests that this method has the potential to be applied towards the extraction of 26 
ctDNA fragments from clinical samples. 27 
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1. Introduction 40 
 Detection of low levels of circulating tumor DNA (ctDNA) holds great promise in 41 
guiding cancer diagnostics, prognosis, and treatment.[1,2] ctDNA is believed to originate from 42 
tumor cells that have undergone apoptosis or necrosis e ulting in the release of tumor DNA into 43 
the bloodstream.[3] However, there is a low abundance of ctDNA in plasma, especially in the 44 
early stages of cancer (i.e., less than 0.01%), and the presence of high levels of wild-type DNA 45 
can increase the probability of false-positive results due to primer mishybridization or mask 46 
present ctDNA.[4] In addition, ctDNA sequences such as KRAS and EGFR are prone to single 47 
nucleotide polymorphisms (SNPs) and differentiation of mutant ctDNA fragments from wild-48 
type DNA is imperative to guiding cancer treatment.[2,5,6] Therefore, to distinguish SNPs from 49 
wild-type DNA, a sequence-specific DNA extraction method is often required to preconcentrate 50 
target ctDNA fragments.  51 
 There are several approaches to achieve sequence-spe ific ctDNA extraction and 52 
preconcentration. Synchronous coefficient of drag alter tion (SCODA) is a novel microfluidic 53 
method for ctDNA preconcentration and analysis.[7] SCODA uses an oligonucleotide-54 
functionalized electrophoresis gel to preconcentrate DNA sequences when exposed to a rotating 55 
electric field. Although SCODA is successful at preconcentrating low concentrations of ctDNA 56 
mutations with limits of detection of 0.001% mutation abundance without PCR amplification, the 57 
technique is expensive and has limited sample throughp t.[8] Commercially-available 58 
streptavidin magnetic beads have been widely used in the extraction of ctDNA.[3,9] In this 59 
approach, target DNA anneals to a biotinylated DNA probe followed by the probe-target 60 
complex binding to streptavidin coated magnetic beads, which are collected using an external 61 
magnet. Differential strand separation at critical temperature (DISSECT) is another magnetic 62 
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bead-based extraction procedure that utilizes a dual-biotinylated probe conjugated to 63 
streptavidin-coated magnetic beads to extract both wild-type and mutant ctDNA fragments.[10] 64 
With DISSECT, the desorption temperature is controlled so that only the mutant DNA desorbs 65 
from the magnetic beads while wild-type DNA remains hybridized to the probe. DISSECT is 66 
highly sensitive and can detect 1 mutant allele in the presence of 10,000 wild-type fragments. 67 
However, magnetic beads are prone to aggregation and sedimentation, which decreases the 68 
amount of DNA extracted.[11,12] The ideal sequence-sp cific DNA extraction method should 69 
rapidly and selectively isolate SNPs from complex media. However, current methods such as 70 
SCODA and DISSECT suffer from high economic costs, edimentation, and time-consuming 71 
purifications steps. Therefore, alternative extraction procedures should be investigated to 72 
improve sample throughput, selectivity, and detection limits. 73 
 An attractive alternative to traditional bead-based approaches is the use of paramagnetic 74 
liquid extraction solvents such as magnetic ionic liquids (MILs). MILs are a subclass of ionic 75 
liquids (ILs) that contain a paramagnetic component in either the cation or anion. MILs exhibit a 76 
number of interesting properties including negligible vapor pressure at room temperature, high 77 
thermal stability, magnetic susceptibility, and tunable physiochemical properties.[13–15] These 78 
properties enable the use of MILs as extraction solvents in a wide range of applications, 79 
including the sequence-specific extraction of DNA.[16,17] In particular, strategies that couple 80 
ion-tagged oligonucleotide (ITO) probes and MILs represent an economical, particle-free 81 
alternative towards sequence-specific DNA extraction with low background DNA co-extraction 82 
and high extraction efficiencies. ITOs are designed to form a duplex with a single-stranded DNA 83 
target and can be captured by the MIL solvent through various interactions, such as hydrophobic 84 
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interactions. ITOs are typically synthesized via the iol-ene click reaction between a 3’ thiol-85 
modified oligonucleotide and an allylimidazolium IL.  86 
Quantitative polymerase chain reaction (qPCR) is an important tool in DNA analysis 87 
capable of rapidly amplifying and quantifying small mounts of DNA. The reaction can be 88 
monitored in real-time using fluorescent probes such as SYBR Green or FAM, eliminating the 89 
lengthy electrophoretic separation step required in end-point PCR.  However, qPCR is highly 90 
susceptible to inhibition and requires an initial DNA purification step in order to obtain accurate 91 
quantification.[18] Current sequence-specific DNA extraction procedures often require a time-92 
consuming extraction step (i.e., up to 60 min).[19] Extraction times can often be dramatically 93 
reduced by employing dispersive liquid-liquid microextraction (DLLME) as opposed to static 94 
extraction methods. DLLME involves dispersing the extraction solvent into small droplets which 95 
significantly increases the surface area of the extraction phase. DLLME methods can take as 96 
little time as 1 min, and the high agitation rate prevents sedimentation of the extraction 97 
solvent.[20–22] MILs have recently been employed as DLLME solvents in order to circumvent 98 
the numerous centrifugation steps required to sedimnt traditionally employed organic 99 
solvents.[23] The paramagnetic properties of MILs can be exploited to  rapidly collect droplets 100 
using a magnet resulting in more efficient extraction procedures. 101 
One major bottleneck in DNA extraction procedures is the recovery step.  Commercial 102 
magnetic beads recommend a 10 min thermal desorption s ep which ultimately reduces sample 103 
throughput. One approach to overcoming this bottleneck is introducing the extraction phase to 104 
the qPCR buffer and using elevated temperatures of qPCR to desorb target DNA to the reaction. 105 
However, introducing magnetic beads or chitosan microparticles to the reaction buffer decreases 106 
the amplification efficiency making quantification unreliable.[24] It has been shown that MILs 107 
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can be directly added to PCR by designing a buffer capable of relieving any inhibition caused by 108 
the MIL with minimal effect on the amplification efficiency.[25] The use of direct-MIL-qPCR 109 
streamlines the extraction procedure by removing time-consuming DNA recovery steps.  110 
Although previously reported ITO-MIL approaches have provided a selective DNA 111 
extraction method capable of extracting large amounts of DNA from cell lysate compared to 112 
commercially available magnetic bead-based methods, the ITO-MIL strategy has only been 113 
applied to high concentrations of target DNA (282 pM) and required lengthy extraction and 114 
desorption steps.[16,26] To overcome the aforementioned disadvantages of previously reported 115 
ITO-MIL methods, a dispersive extraction method was developed to rapidly preconcentrate low 116 
concentrations (3.3 fM) of the mutation prone KRAS oncogene fragment from plasma. DNA-117 
enriched MIL was subsequently incorporated into the qPCR buffer to further increase sample 118 
throughput. The extraction of albumin and DNA by three hydrophobic, manganese(II)-based 119 
MILs consisting of trihexyl(tetradecyl)phosphonium ([P6,6,6,14
+]) 120 
tris(hexafluoroacetylaceto)manganate(II) ([Mn(hfacac)3
-]), trioctylbenzylammonium ([N8,8,8,Bz
+]) 121 
[Mn(hfacac)3
-], and [N8,8,8,Bz
+] 122 
bis(hexafluoroacetylaceto)phenyltrifluoroacetylacetomanganate(II) ([Mn(hfacac)2(Phtfacac)
-]) 123 
were evaluated. MILs were specifically designed to pr vide minimal background DNA and 124 
protein extraction while maintaining qPCR compatibili y. ITOs were designed to contain a 20 nt 125 
oligonucleotide complimentary to the KRAS amplicon. In addition, four ITOs containing either 126 
alkyl or aromatic moieties and different anions were investigated as DNA extraction probes. 127 
Once the ITO annealed to the target sequence, the ITO-DNA duplex was preconcentrated in as 128 
little as 1 min followed by collection of MIL droplets using an external magnet.  Furthermore, 129 
DNA was desorbed from the MIL during qPCR thereby avoiding lengthy desorption steps. 130 
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Incorporation of the DNA-enriched MIL into the qPCR buffer did not significantly affect the 131 
amplification efficiency when extracting KRAS target from pure water or 10-fold diluted plasma. 132 
The ITO-MIL-DLLME method obtained enrichment factors as high as 19.49 ± 1.44 from pure 133 
water, and selectively preconcentrated DNA from a diluted plasma matrix indicating its potential 134 
for the analysis of ctDNA from clinical samples. 135 
2. Materials and Methods 136 
2.1 Reagents and Materials 137 
Manganese(II) chloride tetrahydrate (98.0-101.0%) was purchased from Alfa Aesar (Ward 138 
Hill, MA, USA). Ammonium hydroxide (28-30% solution in water), 1,1,1,5,5,5-139 
hexafluoroacetylacetone (99%), 1-phenyl-4,4,4-trifluoro-1,3-butanedione (99%), and 140 
trioctylamine (97%) were purchased from Acros Organics (Morris Plains, NJ, USA).  Anhydrous 141 
diethyl ether (99.0%) was purchased from Avantor Performance Materials Inc. (Center Valley, 142 
PA, USA). Trihexyl(tetradecyl)phosphonium chloride (97.7%) was purchased from Strem 143 
Chemicals (Newburyport, MA, USA). Ethylenediaminetetraacetic acid (EDTA) (99.4-100.06%), 144 
bovine serum albumin (BSA) (≥96%), allyl bromide, 1-bromooctane (99%), benzylimidazole 145 
(99%), triethylamine (≥99.5%), LC-MS grade acetonitrile (≥99.9%), lyophilized plasma from 146 
human (4% trisodium citrate), deoxyribonucleic acid sodium salt from salmon testes (stDNA), 147 
and magnesium chloride hexahydrate (99.0-102.0%)  were purchased from Sigma-Aldrich (St. 148 
Louis, MO, USA). SYBR Green I (10,000x) was purchased from Life Technologies (Carlsbad, 149 
CA, USA). Urea (>99%) and tris(2-carboxyethyl)phosphine (TCEP) (>98%) were purchased 150 
from P212121 (Ypsilanti, MI, USA). Ammonium persulfate (APS) (≥98.0%), 40% acrylamide, 151 
bis-acrylamide solution 29:1, SsoAdvanced Universal SYBR Green Supermix, and a KRAS, 152 
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human PrimePCRTM SYBR green assay (120 base pair amplicon; additional information can be 153 
found on Bio-Rad’s website) were purchased from Bio-Rad Laboratories (Hercules, CA, USA). 154 
Thiolated, biotinylated, and unmodified oligonucleotides (sequences shown in Table S1) were 155 
purchased from Integrated DNA Technologies (Coralville, IA, USA). PCR caps, tube strips, 156 
sodium chloride, and Dynabeads Myone Steptavidin C1 magnetic beads were purchased from 157 
Thermo Fisher Scientific (Waltham, MA, USA). Tris-HCl was purchased from RPI (Mount 158 
Prospect, IL, USA). Neodymium rod (0.66 T) and cylinder magnets (0.9 T) were purchased from 159 
K&J Magnetics (Pipersville, PA, USA) and used to collect dispersed MIL droplets or magnetic 160 
beads. Deionized water (18.2 MΩ cm), obtained from a Milli-Q water purification system, was 161 
used to prepare all aqueous solutions (Millipore, Bdford, MA, USA).  162 
2.2 Instrumentation  163 
ITO characterization was performed using an Agilent 1260 Infinity high performance 164 
liquid chromatograph (HPLC) with a diode array detector coupled to an Agilent 6230B accurate 165 
mass time of flight (TOF) mass spectrometer with an electrospray source. A Zorbax Extend C18166 
column (50 mm × 2.1 mm i.d. × 1.8 µm particle size) purchased from Agilent Technologies was 167 
used for the separation and characterization of ITOs. The column was equilibrated for 20 min at 168 
0.2 mL min−1 with a mobile phase composition of 95:5 A:B where mobile phase A was 5 mM 169 
triethylammonium acetate (pH 7.4) and B was LC-MS grade acetonitrile. In order to prevent 170 
non-volatile imidazolium salts and urea from entering the mass spectrometer, LC eluent was 171 
diverted to the waste for the first 8 min. Gradient lution was performed using the following 172 
program: 5% B for 5 min, gradient increase 5% to 19.4% B from 5 to 17 min, increased 19.4% to 173 
35% B from 17 to 18 min, held at 35% B from 18 to 20 min, increased 35% B to 100% B from 174 
20 to 30 min, and held at 100% B from 30 to 33 min. The nebulizing gas was set to 35 psi. The 175 
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8
drying (N2) gas flow rate was 9 L min
−1 with a temperature of 350 °C and a capillary voltage of 176 
4000 V. Spectra were acquired from 100-3000 m/z with a scan rate of 1 spectrum sec−1.   177 
HPLC separations were performed on an Agilent Technologies 1260 system with 178 
variable wavelength detection (Santa Clara, CA, USA) to investigate the capability of the 179 
investigated MILs to extract DNA and protein as well as to examine loading of the DNA-ITO 180 
duplex to the MIL phase. A TSKgel DEAE-NPR anion exchange column (35 mm × 4.6 mm i.d. 181 
× 2.5 µm particle size) with a TSKgel DEAE-NPR guard column (5 mm × 4.6 mm i.d. × 5 µm 182 
particle size) was obtained from Tosoh Bioscience (King of Prussia, PA, USA) and used to 183 
examine the DNA and protein extraction ability of the three MILs. When separating and 184 
detecting stDNA, the column was equilibrated with a mobile phase composition of 50:50 A:B 185 
(i.e, mobile phase A: 20 mM Tris-HCl (pH 8) and mobile phase B: 1 M NaCl and 20 mM Tris-186 
HCl (pH 8)). Gradient elution was achieved from 50% mobile phase B and ramping to 100% B 187 
from 0 to 10 min. In the separation of 20 bp DNA, the column was first equilibrated with mobile 188 
phase A for 20 min followed by gradient elution (0% to 50% mobile phase B) from 0 to 10 min 189 
and increased to 100% B from 10 to 15 min. In order to separate BSA, the column was first 190 
equilibrated with mobile phase A for 20 min followed by gradient elution (0% to 50% B) from 0 191 
to 15 min and increased to 100% B from 15 to 20 min. A flow rate of 0.5 mL min−1 was used for 192 
all HPLC separations. DNA and albumin were detected a  260 and 280 nm, respectively. 193 
Denaturing polyacrylamide gel electrophoresis (PAGE) was performed using a Mini 194 
Protean 3 electrophoresis system from Bio-Rad Laboratories with an ECPS 3000/150 power 195 
supply from Pharmacia (Stockholm, Sweden). An 18% polyacrylamide gel was prepared using 7 196 
M urea to separate the ITOs from unreacted oligonucleotides. A 30 min pre-run was performed 197 
at 200 V and 150 W to equilibrate the gel and improve band resolution. Once the sample was 198 
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loaded, the gel was run at 200 V and 150 W for approximately 1 h with an ice bath to cool the 199 
electrophoresis tank. 200 
A Bio-Rad CFX96 Touch Real-time PCR was utilized for qPCR amplification of the 201 
KRAS target using the following program: 2 min initial denaturation at 95 °C followed by 40 202 
cycles comprised of a 5 s denaturation step at 95 °C, a 30 s annealing step at 60 °C, and an 203 
optical detection step. Melt curves of qPCR products were achieved by starting at 65°C for 5 s 204 
and increasing to 95°C in 0.5°C increments. Melt curves analysis of the ITO to a complementary 205 
sequence and sequences containing a 1 or 2 nucleotide (nt) mismatch was achieved using the 206 
following program: initial 5 min denaturation step at 90°C, 10 min annealing step at 20°C, and a 207 
ramp from 20°C for 5 s and increasing to 95°C in 0.5°C increments. 208 
2.3 MIL and ITO synthesis 209 
Chemical structures of the three MILs are shown in Figure 1(1-3). The [NH4
+][Mn(hfacac)3
-] 210 
salt and [P6,6,6,14
+][Mn(hfacac)3
-] MIL were synthesized and characterized using a previously 211 
reported procedure.[27] The [N8,8,8,Bz
+] cation was synthesized as previously reported and212 
characterized using NMR, as shown in Figure S1.[28] The [N8,8,8,Bz
+][Mn(hfacac)3
-] MIL was 213 
synthesized by stirring equimolar amounts of [N8,8,8,Bz
+][Br -] and [NH4
+][Mn(hfacac)3
-] in 30 mL 214 
of methanol overnight. The [NH4
+] hexafluoroacetylacetonate ([hfacac-]) and [NH4
+] 215 
phenyltrifluoroacetylacetonate ([Phtfacac-]) salts were prepared by dissolving either 216 
hexafluoroacetylacetone (hfacac) or phenyltrifluoroacetylacetone (Phtfacac) in 30 mL of ethanol 217 
with equimolar amounts of [NH4
+][OH-]. The product was subsequently dried for 5 hr in a 218 
vacuum oven. The [NH4
+][Mn(hfacac)2(Phtfacac)
-] salt was synthesized by reacting 2 molar 219 
equivalents of [NH4
+][hfacac-], 1 molar equivalent of [NH4
+][Phtfacac-], and 1 molar equivalent 220 
of MnCl2 overnight in ethanol. The [N8,8,8,Bz
+][Mn(hfacac)2(Phtfacac)
-] MIL was synthesized by 221 
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10 
stirring equimolar amounts of [N8,8,8,Bz
+][Br -] and [NH4
+][Mn(hfacac)2(Phtfacac)
-] salts in 30 mL 222 
of methanol overnight. All three MILs were purified using diethyl ether and water and 223 
subsequently dried overnight in a vacuum oven. The MIL solvents were stored in a desiccator 224 
when not in use.  Elemental analysis results were acquired using a PE 2100 Series II combustion 225 
analyzer (Perkin Elmer Inc., Waltham, M.A.).  Carbon/hydrogen/nitrogen (CHN) calculated for 226 
[N888Bz
+][Mn(hfacac)2(Phtfacac)
-]: %C = 54.26, %H = 5.89, %N = 1.24; Found: %C = 53.47, 227 
%H= 5.75, %N = 1.56. Calculated for [P66614
+][Mn(hfacac)3
-]: %C = 48.67, %H = 6.17; Found: 228 
%C = 50.15, %H = 6.16.  Calculated for [N888Bz
+][Mn(hfacac)3
-]: %C = 49.29, %H = 5.49, and 229 
%N = 1.25; Found: %C = 50.22, %H = 5.45, %N = 1.80.  230 
Chemical structures of the four ITOs used in this study are shown in Figure 1(4-7). ITOs 231 
were prepared according to previously reported methods.[16] By reacting the [AOIM+]-KRAS 232 
[Br-] and [ABzIM+]-KRAS [Br-] ITOs with an equimolar amount of KPF6, the [AOIM
+]-KRAS 233 
[PF6
-] and [ABzIM+]-KRAS [PF6
-] ITOs were prepared. All ITOs were characterized using 234 
HPLC-TOF MS, as shown in Table S2 and Figure S2. 235 
2.4 Background DNA and Protein Co-extraction by MILs 236 
 To investigate the protein extraction capabilities of the three MILs, a 20 µL volume of 237 
MIL was added to a 1 mL solution of 1 mg mL-1 BSA and manually agitated for 30 s. After 238 
dispersing the MIL, 20 µL of the aqueous solution was subjected to anion exchange 239 
chromatography for quantitative analysis. To ensure low background DNA co-extraction by the 240 
MIL, two different DNA sequences were examined involving the addition of a 20 µL volume of 241 
MIL to 50 ng/µL stDNA, or 18.3 ng/µL 20 bp DNA. The solution was manually agitated for 30 242 
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11 
s. Subsequently, 20 µL of the aqueous solution was subjected to anion exchange separation for 243 
analysis.  244 
Examining DNA-ITO Duplex Loading to MIL 245 
 To determine the optimum ITO and MIL pair, a 1 µL aliquot of MIL was added to a 60 246 
µL solution containing 25 mM NaCl and 1 ng µL-1 ITO-DNA duplex solution. The solution was 247 
then incubated for 10 min at room temperature. Subsequently, 20 µL of the aqueous phase was 248 
subjected to anion exchange chromatographic analysis.  249 
2.5 Annealing and Capture of Target DNA 250 
The general procedure used to anneal target KRAS template to the ITO and subsequent 251 
extraction using DLLME is shown in Figure 2. A 1 mL solution of 25 mM NaCl, 2×104 copies 252 
µL-1 of KRAS template, and an optimized amount of ITO was prepared in a 5 mL screw cap glass 253 
vial. A 10 µL aliquot was then removed and used as a standard. The DNA solution was heated to 254 
90°C using a Fisher Isotemp 2322 water bath (Rochester, MN, USA) for 2 min to melt the DNA 255 
duplex and then cooled to 30°C for 8 min to anneal the target DNA to the ITO. Subsequently, an 256 
optimized volume of MIL was dispersed using a Barnstead/Thermolyne Type 16700 mixer 257 
(Dubuque, IA, USA) for an optimal amount of time. MIL droplets were collected using a rod 258 
magnet (B = 0.66 T) and subsequently washed with deionized water (18.2 MΩ cm). A 0.3 µL 259 
aliquot of DNA-enriched MIL was then placed into a qPCR tube for downstream analysis.  260 
Sequence-specific DNA extractions using Dynabeads Myone Steptavidin C1 beads were 261 
performed according to the manufacturer’s instructions. A 1 mL solution of 25 mM NaCl, 2×104 262 
copies µL-1 of template, and 332 fM biotinylated probe was prepa d in a 5 mL screw cap glass 263 
vial. A 10 µL aliquot of this solution was used as a tandard. The sample solution was heated for 264 
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5 min at 90°C and then cooled on ice for 5 min. Themagnetic beads (i.e., 10 µg) were washed 265 
three times with 5 mM Tris-HCl (pH 7.5), 0.5 mM EDTA, and 1 M NaCl prior to adding 266 
magnetic beads to the sample solution. The sample was agitated using a New Brunswick 267 
Scientific incubator shaker (Edison, NJ, USA) for 10 min at 250 rpm. Subsequently, the beads 268 
were collected using an external magnet (B = 0.9 T) and washed three times with 5 mM Tris-HCl 269 
(pH 7.5), 0.5 mM EDTA, and 1 M NaCl. The beads were th n suspended in 20 µL of H2O and 270 
heated at 90°C for 10 min to desorb captured DNA. 271 
2.6 qPCR Amplification 272 
The addition of 0.3 µL [P6,6,6,14
+][Mn(hfacac)3
-] MIL to a 20 µL qPCR mixture required 273 
1x SsoAdvanced Supermix, 1x PrimePCR assay mix, 4 mM EDTA, and additional 1x SYBR 274 
Green I. qPCR amplification with 0.3 µL of the [N8,8,8,Bz
+][Mn(hfacac)3
-] MIL was achieved 275 
using the 1x SsoAdvanced Supermix, 1x PrimePCR assay mix, 6.25 mM MgCl2, 4 mM EDTA, 276 
and an additional 0.4x SYBR Green I for a final volume of 20 µL. The addition of 0.3 µL 277 
[N8,8,8,Bz
+][Mn(hfacac)2(Phtfacac)
-] MIL to a 20 µL qPCR mixture required 1x SsoAdvanced 278 
Supermix, 1x PrimePCR assay mix, 2.5 mM MgCl2, 2 mM EDTA, and  additional 1x SYBR 279 
Green I. 280 
The threshold cycle (Cq) was determined using the fluorescence threshold provided by 281 
the Bio-Rad CFX Maestro software and used to determine the amount of the KRAS-ITO duplex 282 
extracted by the hydrophobic MIL.  A standard curve was constructed for KRAS template (see 283 
Figure S3) and to determine the concentration of DNA extracted using the ITO-MIL-DLLME 284 
procedure. The enrichment factors (Ef) obtained for each extraction were calculated using 285 
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equation 1, where CMIL  is the concentration of DNA extracted using the MIL and CStd represents 286 
the concentration of target DNA initially present i the sample. 287 
 288 
 = 	
      Equation 1 289 
3. Results and Discussion 290 
3.1 qPCR Conditions to Mitigate the Inhibitory Effects of MILs 291 
 In order to remove tedious sample handing steps and increase sample throughput, DNA-292 
enriched MIL was incorporated into the qPCR buffer in which DNA is capable of desorbing 293 
from the MIL due to the elevated temperatures requir d for the reaction. However, it has been 294 
previously shown that hydrophobic MILs can dissolve under the elevated temperatures required 295 
for PCR.[29] Solubilized MIL components can inhibit PCR amplification; nevertheless, qPCR 296 
inhibition can be relieved through the addition of EDTA, BSA, additional MgCl2, additional 297 
Tris-HCl, and additional SYBR Green I.  298 
The inhibition of qPCR due to the addition of [P6,6,6,14
+][Mn(hfacac)3
-], 299 
[N8,8,8,Bz
+][Mn(hfacac)3
-], and [N8,8,8,Bz
+][Mn(hfacac)2(Phtfacac)
-] MILs was mitigated by 300 
titrating 0-8 mM MgCl2, 0-8 mM EDTA, and 0-1x SYBR Green I into the buffer. Incorporation 301 
of 0.3 µL of [P6,6,6,14
+][Mn(hfacac)3
-] MIL to the qPCR buffer required 4 mM EDTA and 1x 302 
SYBR Green I, as previously reported.[25] The addition of 0.3 µL of the [N8,8,8,Bz
+][Mn(hfacac)3
-
303 
] MIL to the qPCR buffer was optimized to require 4 mM EDTA, 6.25 mM MgCl2, and 0.4x 304 
SYBR Green I. Inhibition caused by 0.3 µL of the [N8,8,8,Bz
+][Mn(hfacac)2(Phtfacac)
-] MIL 305 
required 4 mM EDTA, 2.5 mM MgCl2, and 1x SYBR Green I in order to achieve amplification. 306 
Addition of EDTA to the MIL-qPCR buffer chelates solubilized anion providing relief to qPCR 307 
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inhibition. Without additional SYBR green in solution, the fluorescence signal remains low 308 
likely due to the partitioning of SYBR Green I to the hydrophobic MIL phase.[30]  309 
The addition of excess oligonucleotides to a PCR reaction can either accelerate the 310 
reaction or lead to the formation of primer-dimers.[31–34] Therefore, to investigate the effect of 311 
the ITO on the reaction, 4×106 copies of ITO were spiked into the qPCR buffer. However, as 312 
shown in Figure S4, spiking ITOs into the qPCR did not affect the Cq nor did the melt curve 313 
indicate the presence of primer-dimers. In this case, it appears that the addition of ITO did not 314 
affect the reaction likely due to the low concentration of the probe. 315 
Examination of the melting temperature (Tm) can be used to differentiate SNPs.[35] 316 
Therefore, the Tm of the qPCR product was examined to investigate whther the MIL-based 317 
DNA extraction or direct qPCR amplification altered the DNA sequence. Figure S5 shows that 318 
the Tm of extracted target DNA was comparable to the KRAS standard (± 0.5 °C) suggesting that 319 
the sequence was not altered due to the MIL. This result is in agreement with previous MIL-320 
based DNA amplification studies.[29] 321 
3.2 MIL and ITO Screening 322 
 An ideal MIL solvent should be capable of capturing the ITO-DNA duplex while not 323 
extracting background DNA and plasma components. However, plasma contains 35-80 mg mL-1 324 
of protein making it an extremely challenging and complex matrix due to the fact that plasma 325 
proteins can inhibit qPCR amplification.[18,36–38] Furthermore, plasma contains high levels of 326 
background DNA presenting a challenge for targeted analysis. Therefore, to prevent co-327 
extraction of background DNA,  manganese(II)-based MILs were investigated as they have been 328 
previously shown to poorly extract DNA.[16,25] In addition, manganese(II) binds poorly to 329 
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albumin, which makes up over 50% of the total protein content of plasma.[39–41] As shown in 330 
Figure 3, the addition of aromatic moieties to eithr the cation or anion component of the MIL 331 
was shown to reduce the amount of BSA extracted. The three MILs were also tested to examine 332 
the extraction efficiency of short (20 bp) and long (20 Kbp) DNA fragments. All three MILs 333 
extracted less than 2% of either DNA sequence, as shown in Figure 3.  334 
 Previously, it was reported that DNA-ITO duplexes interact with the MIL solvent 335 
primarily through hydrophobic interactions.[16] Exchanging the [Br-] anion of the ITO with a 336 
more hydrophobic anion, such as [PF6
-], has the potential to facilitate stronger interactions with 337 
the MIL solvent and possibly improve loading efficiency. As shown in Figure 4, 56.94 ± 1.61% 338 
of the target was extracted by the [P6,6,6,14
+][Mn(hfacac)3
-] MIL using the [AOIM+]-KRAS [PF6
-] 339 
ITO while only 48.18 ± 3.89%, 45.98 ± 3.32%, and 38.59 ± 4.90%  was loaded using the 340 
[AOIM +]-KRAS [Br-], [ABzIM +]-KRAS [Br-], and [ABzIM+]-KRAS [PF6
-] ITOs, respectively. In 341 
addition, incorporation of aromatic moieties into the ITO and MIL structures facilitated π-π 342 
stacking interactions and provided a modest increase in the amount of ITO loaded to the MIL. As 343 
shown in Figure 4, 65.94 ± 9.55% of the [ABzIM+]-KRAS [Br-] ITO-DNA duplex was loaded 344 
onto the [N8,8,8,Bz
+][Mn(hfacac)3
-] MIL whereas only 26.13 ± 3.44%, 37.83 ± 1.28%, and 20.17 ± 345 
2.04%  was loaded using the [AOIM+]-KRAS [Br-], [AOIM +]-KRAS [PF6
-], and [ABzIM+]-KRAS 346 
[PF6
-] ITOs, respectively. Using the [N8,8,8,Bz
+][Mn(hfacac)2(Phtfacac)
-] MIL as an extraction 347 
solvent, 16.56 ± 3.36% [AOIM+]-KRAS [Br-], 42.05 ± 0.72% [AOIM+]-KRAS [PF6
-], 53.69 ± 348 
2.27% [ABzIM+]-KRAS [Br-] ITO, and 25.10 ± 4.91% [ABzIM+]-KRAS [PF6
-] ITO was loaded 349 
onto the MIL solvent, as shown in Figure 4.  350 
3.3 Optimization of the ITO-MIL-DLLME Method 351 
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Cell-free DNA (cfDNA) is present in relatively high concentrations (1-100 pM) in blood, 352 
plasma, and serum.[42] However, certain tumor mutations can comprise less than 0.01% of the 353 
total amount of cfDNA.[43] Therefore, a clinically relevant concentration of 2×104 copies µL-1 354 
(33 fM) of target KRAS fragments was used during optimization. A 1 mL sample volume was 355 
selected in order to maintain the minimum sample voume capable of being dispersed. 356 
 The amount of ITO versus the amount of DNA present in the solution was first 357 
optimized. The sample was initially heated to 90°C to denature the DNA duplex followed by a 358 
cooling step to 30°C. After annealing the ITO to the arget DNA, 6 µL of MIL was added to the 359 
solution. The solution was vortexed for 1 min, and the DNA-enriched MIL was recovered from 360 
the aqueous solution using a rod magnet (B = 0.66 T) and subjected to qPCR analysis. As shown 361 
in Figure S6, a 10-fold excess of either [AOIM+]-KRAS [PF6
-] and [ABzIM+]-KRAS [Br-] ITO 362 
was found to be optimum for the [P6,6,6,14
+][Mn(hfacac)3
-], [N8,8,8,Bz
+][Mn(hfacac)3
-], and 363 
[N8,8,8,Bz
+][Mn(hfacac)2(Phtfacac)
-] MILs. Target DNA can either reanneal to the compli entary 364 
sequence or anneal to the ITO. Therefore, to increase the probability that target DNA anneals to 365 
the ITO, an excess amount of ITO was needed. However, high concentrations of ITO may result 366 
in the MIL extracting unhybridized ITO instead of the desired ITO-DNA complex.   367 
 The volume of MIL dispersed in the solution was alo optimized for all three MILs. A 368 
volume of 8 µL of [P6,6,6,14
+][Mn(hfacac)3
-] MIL was found to be optimum while dispersing 6 µL369 
and 4 µL of [N8,8,8,Bz
+][Mn(hfacac)3
-] and [N8,8,8,Bz
+][Mn(hfacac)2(Phtfacac)
-] MILs, respectively, 370 
produced the highest extraction efficiencies, as shown in Figure S7. Larger volumes of MIL 371 
generally resulted in lower Ef as DNA can be diluted within the MIL.[44]  372 
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 Additionally, the extraction time was optimized to achieve the highest Ef in the shortest 373 
amount of time. As shown in Figure S8, an extraction time of 3 min was optimum for the 374 
[P6,6,6,14
+][Mn(hfacac)3
-] MIL while 1 min was optimum for the [N8,8,8,Bz
+][Mn(hfacac)3
-] and 375 
[N8,8,8,Bz
+][Mn(hfacac)2(Phtfacac)
-] MILs. After the optimum times for the 376 
[P6,6,6,14
+][Mn(hfacac)3
-] and [N8,8,8,Bz
+][Mn(hfacac)3
-] MILs, a sharp decrease in the amount of 377 
DNA extracted was observed.  378 
3.4 Comparison to Commercial Sequence-Specific Magnetic Beads 379 
 Streptavidin magnetic beads have been used to capture specific ctDNA mutations from 380 
clinical plasma samples.[3,9,10]  A significant drawb ck to using magnetic beads is their 381 
propensity to aggregate and sediment, which is especially problematic when extraction of low 382 
concentrations of target DNA requires the beads to be suspended for long periods of time. MILs 383 
are uniquely capable of overcoming these issues as they can be easily dispersed into fine droplets 384 
that remain suspended in solution for extended periods of time.[45] Due to these properties, 385 
MILs have the potential to provide unique advantages over commercial magnetic beads in 386 
sequence-specific DNA extractions. The ITO-MIL-DLLME procedure was compared to the 387 
commercial Dynabeads Myone streptavidin C1 magnetic beads. As shown in Figure 5a, 388 
extractions performed using the [P6,6,6,14
+][Mn(hfacac)3
-] and [N8,8,8,Bz
+][Mn(hfacac)3
-] MILs 389 
produced Ef values of 19.49 ± 1.44 and 16.44 ± 2.21 outperforming the commercial streptavidin 390 
Dynabeads, which provided a respectable Ef of 9.73 ± 0.42 from pure water. When examining 391 
the amount of DNA co-extracted by the MIL and magnetic beads, the optimized extraction was 392 
performed without either the ITO or biotinylated probe. As shown in Figure 5a, a low Ef from 393 
pure water was obtained without ITO and biotinated probe present in solution. The limited co-394 
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extraction of DNA by the MIL solvent indicates that DNA extracted can be attributed to the ITO 395 
or the biotinylated probe.  396 
 When comparing the extraction of KRAS target from 10-fold diluted plasma using the 397 
three MILs and the commercial magnetic beads, the [ABzIM+]-KRAS [Br-] ITO and 398 
[N8,8,8,Bz
+][Mn(hfacac)3
-] MIL produced the highest Ef, as shown in Figure 5b. The 399 
[N8,8,8,Bz
+][Mn(hfacac)2(Phtfacac)
-] MIL experienced only a two-fold decrease in Ef, which may 400 
be linked to the low BSA extraction efficiency associated with this MIL.   However, extractions 401 
using the magnetic beads from 10-fold diluted plasm produced an Ef  of  only 1.30 ± 0.07, 402 
possibly due to the biotinylated probe interacting with plasma proteins.[46] This is supported by 403 
the fact that the Ef obtained using streptavidin-coated magnetic beads, with or without the 404 
biotinylated probe, were within error (i.e., 1.25 ± 0.18). As shown in Figure 5b, low Ef values 405 
were achieved when the ITO was not present in solution suggesting that the ITO plays a 406 
dominant role in preconcentrating DNA from the plasm  solution. However, selectivity was lost 407 
when performing extractions with the steptavidin-coated magnetic beads from 10-fold diluted 408 
plasma. 409 
In order to determine whether the ITO-MIL-DLLME-qPCR method could be used for 410 
accurate quantification, calibration curves for each MIL were constructed by performing a series 411 
of five extractions at different concentration levels followed by the determination of 412 
amplification efficiency using equation 2. Ideally, the amplification efficiency should range 413 
between 90-110%  414 
 = 10(

) − 1 ∗ 100%     Equation 2 415 
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indicating that DNA is successfully duplicated with each cycle and that quantification can be 416 
achieved.[47] It was observed that all three MILs did not significantly alter the amplification 417 
efficiency when incorporated into the qPCR buffer. The [P6,6,6,14
+][Mn(hfacac)3
-] MIL produced 418 
an efficiency of 100.1%, while the [N8,8,8,Bz
+][Mn(hfacac)3
-] MILs exhibited an efficiency of 419 
107.9%, and the [N8,8,8,Bz
+][Mn(hfacac)2(Phtfacac)
-] MIL enabled an efficiency of 107.9%, as 420 
shown in Figure 6. Calibration curves from 10-fold diluted plasma were also constructed for all 421 
three MILs to determine if quantification could be achieved from a more complex medium. As 422 
shown in Figure 7, the amplification efficiencies associated with the extraction of KRAS from 423 
10-fold diluted plasma fell between 90-110% with the addition of the [P6,6,6,14
+][Mn(hfacac)3
-], 424 
[N8,8,8,Bz
+][Mn(hfacac)3
-], and [N8,8,8,Bz
+][Mn(hfacac)2(Phtfacac)
-] MIL to the qPCR buffer 425 
resulting in efficiencies of 106.3%, 109.3%, and 103.5% respectively. Amplification efficiencies 426 
obtained from the ITO-MIL-DLLME procedure in pure water and diluted plasma indicate that 427 
there is little inhibition attributed to adding manganese(II)-based MILs to the qPCR buffer and 428 
that this method can be used for quantification purposes. 429 
3.5 Selectivity of the ITO-MIL-DLLME Method 430 
The detection of low abundance ctDNA is of particular importance for early cancer 431 
detection, prognosis, and treatment monitoring.[48] However, several common ctDNA 432 
fragments are SNPs that complicate ctDNA detection.[2] In order to investigate the selectivity of 433 
the ITO probes for the complementary sequence and 1-2 nt mismatch, melt curve analysis was 434 
performed. If the oligonucleotides are not complimentary, the Tm will decrease indicating 435 
instability of the hybridization.[49] Therefore, toexamine the selectivity of the ITOs towards 436 
target DNA, the Tm of the ITO to a complementary oligonucleotide (20 nt), 1 nt mismatch (20 437 
nt), and 2 nt mismatch (20 nt) was examined. Figure S9 shows that the Tm significantly 438 
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decreased when examining the hybridization of the ITO to the 1 nt mismatch, and a Tm could not 439 
be determined when hybridizing the [AOIM+]-KRAS [PF6
-], [ABzIM +]-KRAS [Br-], and 440 
[ABzIM +]-KRAS [PF6
-] ITOs to the 2 nt mismatch.  441 
Background cfDNA in cancer patients is approximately he same length as ctDNA (i.e, 442 
about 166 bp) and is present in high concentrations, typically 0-1000 ng mL-1 for cancer patients 443 
with mutation abundances less than 0.01%.[4,8,50] To examine the effect of background DNA 444 
on the ITO-MIL-DLLME method, stDNA was sheared to around 150 bp and spiked into the 445 
aqueous sample. stDNA was sheared using a sonication method involving 30 s cycles (30s of 446 
sonication followed by a 30 s rest period) for 1 h and verified by gel electrophoresis, as shown in 447 
Figure S10a. Figure S10b shows that the Ef did not significantly decrease when performing 448 
extractions from a sample solution containing 2×104 copies µL-1 of target KRAS and 1000 ng 449 
mL-1 of sheared stDNA (mutation abundance of 0.009%) indicating that clinically-relevant 450 
concentrations of background cfDNA do not have a significant effect on the extraction of low-451 
abundance target sequences.  452 
4. Conclusions 453 
 Circulating tumor DNA is difficult to isolate due to the presence of SNPs and large 454 
amounts of background DNA and proteins in human plasma. In this study, three hydrophobic 455 
MILs were designed and synthesized to function as liquid supports in the capture of the target 456 
ITO duplex without co-extraction of background DNA or protein. The fine dispersion of MIL 457 
solvent facilitated the formation of droplets with high surface area to capture the target ITO 458 
duplex without sedimentation. After collecting the MIL droplets on a magnetic rod, the MILs 459 
were directly added to qPCR using specially designed buffers that mitigated inhibition from 460 
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MILs during the thermal cycling process. Incorporation of the manganese(II)-based MILs to the 461 
qPCR buffer did not significantly affect the amplification efficiency even when extractions were 462 
performed from diluted human plasma, indicating no significant inhibition. Target KRAS DNA 463 
was preconcentrated from pure water and 10-fold diluted plasma in as little as 1 min using the 464 
[P6,6,6,14
+][Mn(hfacac)3
-], [N8,8,8,Bz
+][Mn(hfacac)3
-], and [N8,8,8,Bz
+][Mn(hfacac)2(Phtfacac)
-] MILs. 465 
Compared to commercially-available streptavidin magnetic beads, the ITO-MIL-DLLME 466 
approach using the [N8,8,8,Bz
+][Mn(hfacac)3
-] and [N8,8,8,Bz
+][Mn(hfacac)2(Phtfacac) 
-] MILs 467 
produced a higher Ef when extracting target DNA from diluted plasma. The magnetic beads were 468 
unable to selectively preconcentrate target DNA from 10-fold diluted plasma while the ITO-MIL 469 
procedure maintained selectivity towards the ITO-DNA duplex. The ability of the ITO-MIL 470 
system to selectively preconcentrate low concentrations of target DNA from diluted plasma 471 
indicates the promise that the ITO-MIL-DLLME method has in the detection of ctDNA 472 
fragments from clinical samples.  473 
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 643 
Figure Legends 644 
Figure 1: Chemical structures of the manganese(II)-based hydrophobic MILs (1-3) and octyl- 645 
and benzyl-imidazolium-based ITO (4-7) structures used for all experiments.  646 
Figure 2: General extraction procedure used to capture target KRAS DNA. DNA-enriched MIL 647 
was added to the reaction buffer for qPCR detection. 648 
Figure 3: Extraction efficiency of BSA (blue), stDNA (red), and 20 bp DNA (green) using the 649 
[P6,6,6,14
+] [Mn(hfacac)3
-], [N8,8,8,Bz
+] [Mn(hfacac)3
-], and [N8,8,8,Bz
+][Mn(hfacac)2(Phtfacac)
-] 650 
MILs. BSA concentration: 1 mg mL-1, stDNA concentration: 50 ng µL-1, 20 bp DNA 651 
concentration: 18.3 ng µL-1; sample volume: 1 mL; agitation time: 30 s; MIL volume: 20 µL.  652 
Figure 4. Loading efficiencies of the ITO-DNA duplex to the MIL phase using the [AOIM+]-653 
KRAS [Br-], [AOIM +]-KRAS [PF6
-], [ABzIM +]-KRAS [Br-], and [ABzIM+]-KRAS [PF6
-] ITOs 654 
and [P6,6,6,14
+][Mn(hfacac)3
-] (blue), [N8,8,8,Bz
+][Mn(hfacac)3
-] (green), and 655 
[N8,8,8,Bz
+][Mn(Phtfacac)(hfacac)2
-] (purple) MILs. ITO concentration: 1 ng µL-1; KRAS 656 
complement: 1 ng µL-1; NaCl concentration: 25 mM; sample volume: 60 µL; MIL volume: 1 µL; 657 
extraction time: 10 min. 658 
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Figure 5. Enrichment factor obtained for the sequence-specific extraction of KRAS target using 659 
the [P6,6,6,14
+] [Mn(hfacac)3
-] MIL, [N 8,8,8,Bz
+][Mn(hfacac)3
-] MIL , [N 8,8,8,Bz
+] 660 
[Mn(hfacac)2(Phtfacac)
-] MIL, and Dynabeads Myone Steptavidin C1 magnetic beads from pure 661 
water (a) and 10-fold diluted plasma (b) with (blue) and without (red) ITO or biotinylated probe. 662 
[P6,6,6,14
+] [Mn(hfacac)3
-] MIL conditions: KRAS template concentration: 2×104 copies µL-1, 663 
amount of [AOIM+]-KRAS [PF6
-] ITO relative to DNA: 10x, NaCl concentration: 25 mM, 664 
sample volume: 1.0 mL, MIL volume: 8 µL; extraction time: 3 min. [N8,8,8,Bz
+][Mn(hfacac)3
-] 665 
MIL conditions: KRAS template concentration: 2×104 copies µL-1, amount of [ABzIM+]-KRAS 666 
[Br-]  relative to DNA: 10x, NaCl concentration: 25 mM, sample volume: 1.0 mL, MIL volume: 667 
6 µL: extraction time: 1 min. [N8,8,8,Bz
+] [Mn(hfacac)2(Phtfacac)
-] MIL conditions: KRAS 668 
template concentration: 2×104 copies µL-1, amount of [ABzIM+]-KRAS [Br-]  relative to DNA: 669 
10x, NaCl concentration: 25 mM, sample volume: 1.0 mL, MIL volume: 4 µL; extraction time: 1 670 
min. Dynabeads Myone Steptavidin C1 magnetic beads conditions: KRAS template 671 
concentration: 2×104 copies µL-1, concentration of biotinylated probe: 332 fM, NaCl 672 
concentration: 25 mM, mass of magnetic beads: 10 µg; sample volume: 1.0 mL; extraction time: 673 
10 min; agitation rate: 250 rpm; desorption time: 10 min; desorption volume: 20 µL. 674 
 675 
 676 
 677 
Figure 6: Standard curves generated using the optimized MIL-DL ME method for the (a) 678 
[P6,6,6,14
+] [Mn(hfacac)3
-], (b) [N8,8,8,Bz
+][Mn(hfacac)3
-], (c) [N8,8,8,Bz
+] [Mn(hfacac)2(Phtfacac)
-] 679 
MILs as extraction solvents. [P
6,6,6,14
+
] [Mn(hfacac)
3
-
] MIL conditions: KRAS template 680 
concentration: 2×104 copies µL-1, amount of [AOIM+]-KRAS [PF6
-]  relative to DNA: 10x, NaCl 681 
concentration: 25 mM, sample volume: 1.0 mL, MIL volume: 8 µL; extraction time: 3 min. 682 
[N
8,8,8,Bz
+
][Mn(hfacac)
3
-
] MIL conditions: KRAS template concentration: 2×104 copies µL-1, 683 
amount of [ABzIM+]-KRAS [Br-]  relative to DNA: 10x, NaCl concentration: 25 mM, sample 684 
volume: 1.0 mL, MIL volume: 6 µL: extraction time: 1 min. [N
8,8,8,Bz
+
] [Mn(hfacac)
2
(Phtfacac)
-
] 685 
MIL conditions: KRAS template concentration: 2×104 copies µL-1, amount of [ABzIM+]-KRAS 686 
[Br-] ITO relative to DNA: 10x, NaCl concentration: 25 mM, sample volume: 1.0 mL, MIL 687 
volume: 4 µL; extraction time: 1 min. 688 
 689 
Figure 7:  Standard curves generated using the optimized MIL-DL ME method from 10-fold 690 
diluted plasma for the (a) [P6,6,6,14
+] [Mn(hfacac)3
-], (b) [N8,8,8,Bz
+][Mn(hfacac)3
-], (c) [N8,8,8,Bz
+] 691 
[Mn(hfacac)2(Phtfacac)
-] MILs as extraction solvents. [P
6,6,6,14
+
] [Mn(hfacac)
3
-
] MIL conditions: 692 
KRAS template concentration: 2×104 copies·µL-1, amount of [AOIM+]-KRAS [PF6
-] ITO relative 693 
to DNA: 10x, NaCl concentration: 25 mM, sample volume: 1.0 mL, MIL volume: 8 µL; 694 
extraction time: 3 min. [N
8,8,8,Bz
+
][Mn(hfacac)
3
-
] MIL conditions: KRAS template concentration: 695 
2×104 copies·µL-1, amount of [ABzIM+]-KRAS [Br-] ITO relative to DNA: 10x, NaCl 696 
concentration: 25 mM, sample volume: 1.0 mL, MIL volume: 6 µL: extraction time: 1 min. 697 
[N
8,8,8,Bz
+
][Mn(hfacac)
2
(Phtfacac)
-
] MIL conditions: KRAS template concentration: 2×104 698 
copies·µL-1, amount of [ABzIM+]-KRAS [Br-] ITO relative to DNA: 10x, NaCl concentration: 25 699 
mM, sample volume: 1.0 mL, MIL volume: 4 µL; extraction time: 1 min. 700 
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Highlights: 
• Ion-tagged olignonucleotides (ITO) were synthesized to anneal to KRAS 
fragment 
• Magnetic ionic liquids (MIL) were developed to exhibit high ITO loading 
efficiency 
• Preconcentrated DNA was analyzed by directly adding MIL to qPCR 
• qPCR amplification efficiency was not affected extracting from diluted-plasma 
• ITO-MIL approach outperformed steptavidin magnetic beads from diluted 
plasma  
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Declaration of interests 
 
☒ The authors declare that they have no known competing financial interests or personal relationships 
that could have appeared to influence the work reported in this paper. 
 
☐The authors declare the following financial interests/personal relationships which may be considered 
as potential competing interests:  
 
 
 
 
 
 
